Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 865.0	$ 588.0	$ 491.4
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	0	0	12.4
Depreciation and amortization	294.8	255.5	250.2
Share based compensation	75.7	62.2	65.7
Impairment of intangible assets	16.0	42.7	0
Gain on sale of non-current investments	(23.5)	(11.1)	(55.2)
Loss/(gain) on sale of product rights	6.0	(16.5)	(6.3)
Other	16.1	9.1	14.6
Movement in deferred taxes	(14.5)	(15.0)	(98.8)
Equity in (earnings)/losses of equity method investees	(2.5)	(1.4)	0.7
Changes in operating assets and liabilities:
Increase in accounts receivable	(134.0)	(114.4)	(212.3)
Increase in sales deduction accrual	80.5	222.6	134.7
Increase in inventory	(64.4)	(58.2)	(38.7)
(Increase)/decrease in prepayments and other assets	(36.8)	(40.3)	30.9
(Decrease)/increase in accounts payable and other liabilities	(10.0)	25.9	38.6
Returns on investment from joint venture	5.2	5.8	4.9
Cash flows used in discontinued operations	0	0	(5.9)
Net cash provided by operating activities	1,073.6	954.9	626.9
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	6.2	6.3	(3.9)
Purchases of subsidiary undertakings, net of cash acquired	(725.0)	(449.6)	(83.3)
Payments on foreign exchange contracts related to Movetis NV ("Movetis") acquisition	0	(33.4)	0
Purchases of non-current investments	(10.7)	(2.9)	(0.9)
Purchases of property, plant and equipment ("PPE")	(194.3)	(326.6)	(254.4)
Purchases of intangible assets	(5.2)	(2.7)	(7.0)
Proceeds from disposal of non-current investments and PP&E	106.0	2.3	20.2
Proceeds/deposits received on sales of product rights	12.0	2.0	0
Proceeds from disposal of subsidiary undertakings	0	0	6.7
Returns of equity investments and proceeds from short term investments	1.8	7.2	0.2
Net cash used in investing activities	(809.2)	(797.4)	(322.4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from drawing of revolving credit facility ("RCF")	30.0	0	0
Repayment of RCF	(30.0)	0	0
Repayment of debt acquired with ABH	(13.1)	0	0
Payment under building finance obligation	(1.5)	(2.4)	(4.7)
Extinguishment of building finance obligation	0	(43.1)	0
Excess tax benefit of stock based compensation	31.4	6.5	16.8
Proceeds from exercise of options	13.4	11.2	14.6
Payment of facility arrangement costs	0	(8.0)	0
Payment of dividend	(73.8)	(62.0)	(54.4)
Payments to acquire shares by ESOT	(151.8)	(1.7)	(1.0)
Net cash used in financing activities	(195.4)	(99.5)	(28.7)
Effect of foreign exchange rate changes on cash and cash equivalents	0.4	(6.3)	4.9
Net increase in cash and cash equivalents	69.4	51.7	280.7
Cash and cash equivalents at beginning of period	550.6	498.9	218.2
Cash and cash equivalents at end of period	620.0	550.6	498.9
Supplemental information associated with continuing operations:
Interest paid	(33.3)	(25.9)	(31.9)
Income taxes paid	(286.1)	(329.2)	(223.2)
Non cash investing and financing activities:
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment in Virochem Pharma, Inc. ("Virochem")	0	9.1	50.8
Building financing obligation	$ 0	$ 0	$ 7.1